陈轶渊拥有英国爱丁堡大学结构生物学博士学位，师从爱丁堡皇家学会院士Walkinshaw教授，长期从事晶状体蛋白结构与功能、蛋白化学、生物光子学及眼科诊疗技术研究，已入选湖州南太湖精英计划和浙江省千人计划。陈轶渊与英国三院院士Desmond Smith教授合作，围绕白内障形成机制及晶状体蛋白功能恢复，主导建立ACQA活性晶状体蛋白量化分析诊断技术和PPM蛋白光化学调控技术，形成“检测+诊断+治疗”一体化技术体系。2021年回国创办博也生物，聚焦智能眼科医疗器械及无创诊疗设备研发，推动产品在欧洲和中国同步完成临床研究并进入注册申报阶段。

Chen Yiyuan holds a Ph.D. in Structural Biology from the University of Edinburgh, where he studied under Professor Walkinshaw, a Fellow of the Royal Society of Edinburgh. He has long been engaged in research on lens protein structure and function, protein chemistry, biophotonics, and ophthalmic diagnostic and therapeutic technologies, and has been selected for the Huzhou South Taihu Elite Program and the Zhejiang Provincial Thousand Talents Program.

In collaboration with Professor Desmond Smith, a Fellow of the UK’s three national academies, Chen Yiyuan led the development of the ACQA (Active Crystallin Quantitative Analysis) diagnostic technology and the PPM (Protein Photochemical Modulation) technology, focusing on cataract formation mechanisms and restoration of lens protein function. Together, these technologies established an integrated platform combining detection, diagnosis, and treatment.

In 2021, Chen Yiyuan returned to China to found Boye Bio, focusing on the development of intelligent ophthalmic medical devices and non-invasive diagnostic and therapeutic technologies. Under his leadership, the company has completed clinical studies in both Europe and China, with products advancing into regulatory registration stages simultaneously in the two markets.